Coramsine(Coramsine) - 药物靶点：IL-6R_专利_临床

概要

基本信息

药物类型

小分子化药

别名-

靶点

IL-6R

作用机制

IL-6 receptor family antagonists

治疗领域

肿瘤皮肤和肌肉骨骼疾病泌尿生殖系统疾病

在研适应症-

非在研适应症

黑色素瘤肿瘤肾细胞癌

原研机构

Curacel International Pty Ltd

在研机构-

非在研机构

Creative Eye Ltd.

最高研发阶段终止临床2期

首次获批日期-

最高研发阶段(中国)-

特殊审评-

登录后查看时间轴

关联

2

项与 Coramsine 相关的临床试验

ACTRN12606000330549 / Not yet recruiting临床2期

An Open Label, Multi Centre, Phase II Study to Evaluate the Safety and Efficacy of Coramsine Injection in Patients with Melanoma

开始日期2006-10-01

申办/合作机构

Solbec Pharmaceuticals Ltd.

ACTRN12606000099527 / Not yet recruiting临床2期

An Open Label, Multi Centre, Phase II Study to Evaluate the Safety and Efficacy of Coramsine Injection in Patients with Renal Cell Carcinoma

开始日期2006-06-30

申办/合作机构

Solbec Pharmaceuticals Ltd.

100 项与 Coramsine 相关的临床结果

登录后查看更多信息

100 项与 Coramsine 相关的转化医学

登录后查看更多信息

100 项与 Coramsine 相关的专利（医药）

登录后查看更多信息

1

项与 Coramsine 相关的文献（医药）

2006-03-01·Journal of Immunotherapy4区 · 医学

Antitumor Efficacy of the Novel Chemotherapeutic Agent Coramsine Is Potentiated by Cotreatment With CpG-Containing Oligodeoxynucleotides

4区 · 医学

Article

作者: Carter, Stephen J. ; van der Most, Robbert G. ; Robinson, Cleo ; Lake, Richard A. ; Aarons, Simon ; Currie, Andrew ; Himbeck, Robyn ; Larma, Irma

Coramsine is a novel chemotherapeutic agent isolated from Solanum linnaeanum (devil's apple). Topical treatment provides clinical benefit for skin tumors. To evaluate the potential broader applicability of the drug, its in vivo anticancer efficacy in a murine model of malignant mesothelioma and its mode of action were investigated. Systemic administration of coramsine slowed tumor growth and prolonged survival time. Importantly, the antitumor efficacy of coramsine was enhanced when treatment was combined with stimulation of innate immunity using unmethylated CpG-containing oligodeoxynucleotides (ODNs). Combination treatment further slowed tumor growth and provided a survival benefit. Coramsine seems to kill tumor cells by direct cell lysis. Using 2 different assays to detect apoptosis (caspase activation and DNA fragmentation), we found no evidence that coramsine induces any form of programmed cell death. The fact that the efficacy of coramsine is potentiated by CpG ODNs suggests that coramsine-induced cell death is an immunologic null event.

100 项与 Coramsine 相关的药物交易

登录后查看更多信息

研发状态

10 条进展最快的记录,

登录

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
黑色素瘤	临床2期	澳大利亚	Creative Eye Ltd.	-
肿瘤	临床2期	美国	Creative Eye Ltd.	-
肾细胞癌	临床2期	澳大利亚	Creative Eye Ltd.	-

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


ASCO2006	临床1期	HR阳性/HER2低表达实体瘤	27	Coramsine	(鏇網願壓醖網膚憲鏇繭) = 襯醖範鬱壓膚廠壓築鏇衊膚鹹鏇繭鑰壓襯鏇鑰 (鹽鹹製鑰網壓網醖繭壓 )	-	2006-06-20
ASCO2005	临床1期	HR阳性/HER2低表达实体瘤	19	Coramsine	(襯積襯襯蓋構糧糧膚艱) = 網膚廠壓壓構積襯構願衊蓋餘衊範餘蓋襯鑰艱 (蓋壓顧構鹽淵獵餘艱齋 )	-	2005-06-01